{"id":177373,"date":"2026-01-23T07:54:56","date_gmt":"2026-01-23T12:54:56","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=177373"},"modified":"2026-02-04T11:03:51","modified_gmt":"2026-02-04T16:03:51","slug":"syngene-international-reports-marginal-revenue-growth-and-sharp-profit-decline-in-q3-fy26-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/syngene-international-reports-marginal-revenue-growth-and-sharp-profit-decline-in-q3-fy26-results\/","title":{"rendered":"Syngene International reports marginal revenue growth and sharp profit decline in Q3 FY26 results"},"content":{"rendered":"\n

Current Status Overview<\/h2>\n\n\n\n

Syngene International Ltd is an India-based contract research, development, and manufacturing services company serving pharmaceutical and biotechnology clients. The company reported muted revenue growth and significant profit contraction in its most recent quarterly results.<\/p>\n\n\n\n

Share Price Performance<\/h2>\n\n\n\n

The company\u2019s shares were trading around INR 545\u2013558 on the NSE as of the latest session. The stock has declined in recent months and remains below its 52-week high.<\/p>\n\n\n\n

Revenue Performance<\/h2>\n\n\n\n

Revenue for the last three months was approximately INR 917 crore. Revenue for the last six months totaled about INR 1,828 crore. Revenue for the last nine months stood at roughly INR 2,703 crore.<\/p>\n\n\n\n

Market Analysis<\/h2>\n\n\n\n

Syngene operates in the global CRDMO segment alongside multinational and regional peers. Industry demand remains stable, though margin pressure persists across the sector.<\/p>\n\n\n\n

Analyst Commentary<\/h2>\n\n\n\n

Public analyst commentary remains mixed following the latest earnings release. No clear consensus shift has been reported.<\/p>\n\n\n\n

Mergers & Acquisitions<\/h2>\n\n\n\n

Syngene completed the acquisition of a US-based biologics manufacturing facility in 2025. No additional M&A activity has been reported recently.<\/p>\n\n\n\n

Outlook<\/h2>\n\n\n\n

The company\u2019s outlook remains cautious amid profitability challenges. Future performance will depend on contract execution and cost management.<\/p>\n\n\n\n

Revenue Chart<\/p>\n\n\n\n

\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

Current Status Overview Syngene International Ltd is an India-based contract research, development, and manufacturing services company serving pharmaceutical and biotechnology clients. The company reported muted revenue growth and significant profit contraction in its most recent quarterly results. Share Price Performance The company\u2019s shares were trading around INR 545\u2013558 on the NSE as of the latest […]<\/p>\n","protected":false},"author":2394,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,392,5,8],"tags":[14660,10169,14659],"class_list":["post-177373","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-earnings","category-latest","category-technology-stocks","tag-crdmo","tag-earnings","tag-syngene-international"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":139061,"url":"https:\/\/alphastreet.com\/india\/syngene-reported-a-5-rise-in-its-net-profit-for-q3fy23\/","url_meta":{"origin":177373,"position":0},"title":"Syngene reported a 5% rise in its net profit for Q3FY23","author":"Chirag Gupta","date":"January 24, 2023","format":false,"excerpt":"Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted in Q3 FY22. Revenue from operations jumped 22.5% to INR 785.90 crore in the quarter ended 31 December 2022 as compared to INR 641.40 crore recorded in Q3\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ecdf316b-951d-48b1-9dc5-4071d6dc1af6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ecdf316b-951d-48b1-9dc5-4071d6dc1af6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ecdf316b-951d-48b1-9dc5-4071d6dc1af6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ecdf316b-951d-48b1-9dc5-4071d6dc1af6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ecdf316b-951d-48b1-9dc5-4071d6dc1af6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/ecdf316b-951d-48b1-9dc5-4071d6dc1af6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":139023,"url":"https:\/\/alphastreet.com\/india\/shares-of-biocon-research-arm-soars-as-it-reports-23-rise-in-its-revenue\/","url_meta":{"origin":177373,"position":1},"title":"Shares of Biocon research arm soars as it reports 23% rise in its revenue","author":"Chirag Gupta","date":"January 24, 2023","format":false,"excerpt":"Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted in Q3 FY22. Revenue from operations jumped 22.5% to INR 785.90 crore in the quarter ended 31 December 2022 as compared to INR 641.40 crore recorded in Q3\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"trending stocks high volatility","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/Trending-stocks.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":144208,"url":"https:\/\/alphastreet.com\/india\/syngene-international-q4fy23-results-out-revenue-rises-by-31\/","url_meta":{"origin":177373,"position":2},"title":"Syngene International Q4FY23 results out, revenue rises by 31%","author":"Chirag Gupta","date":"April 26, 2023","format":false,"excerpt":"Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":172182,"url":"https:\/\/alphastreet.com\/india\/syngene-q2-fy26-earnings-results\/","url_meta":{"origin":177373,"position":3},"title":"Syngene Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 6, 2025","format":false,"excerpt":"Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Syngene Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":144221,"url":"https:\/\/alphastreet.com\/india\/syngene-reported-21-percent-rise-in-its-q4fy23-net-profit\/","url_meta":{"origin":177373,"position":4},"title":"Syngene reported 21 percent rise in its Q4FY23 net profit","author":"Chirag Gupta","date":"April 26, 2023","format":false,"excerpt":"Syngene reported Total revenue for Q4 FY23 of \u20b9994 Crore, up from \u20b9759 Crore year on year, a growth of 31%.While, consolidated Net Profit of \u20b9179 Crore, up 21% from \u20b9147 Crore in the same quarter of the previous year. The Earnings per Share is \u20b94.43, up 21% from \u20b93.67\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/becd0c4d-d7cf-455d-8d8f-236b743729c8.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/becd0c4d-d7cf-455d-8d8f-236b743729c8.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/becd0c4d-d7cf-455d-8d8f-236b743729c8.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/becd0c4d-d7cf-455d-8d8f-236b743729c8.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/becd0c4d-d7cf-455d-8d8f-236b743729c8.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/becd0c4d-d7cf-455d-8d8f-236b743729c8.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170228,"url":"https:\/\/alphastreet.com\/india\/syngene-q1-fy26-earnings-results\/","url_meta":{"origin":177373,"position":5},"title":"Syngene Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 15, 2025","format":false,"excerpt":"Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Syngene Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2394"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=177373"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177373\/revisions"}],"predecessor-version":[{"id":177381,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177373\/revisions\/177381"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=177373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=177373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=177373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}